Legal Commentary on the GSK China Bribery Case from a China Law Perspective
ANALYSIS: The Chinese investigation of GlaxoSmithKline should serve as a wake-up call, and the shareholders of companies in China should consider undertaking internal due diligence to ensure that existing compliance programs are properly understood and implemented.
To read more
Subscribe to Global Investigations Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Investigations Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10